Abstract: A novel method for synthesizing NCA compounds. Also, a new use of a peptide coupling agent. The method makes it possible to obtain NCA compounds from ?-amino-acids, under mild and non-racemic reaction conditions, and in the absence of constraining reagents of use, such as phosgene, which may lead to the formation of undesirable by-products.

Abstract: A method for manufacturing a part made of composite material in which an adhesion promoter is grafted to a coating present on the fibre surface as well as to a ceramic precursor resin. Afterwards, a ceramic matrix phase is formed in the porosity of the fibre preform by pyrolysis of the polymerised resin.

Abstract: A method for manufacturing a part made of composite material includes forming a ceramic matrix phase in pores of a fibrous preform by pyrolysis of a cross-linked copolymer ceramic precursor, the cross-linked copolymer including a first precursor macromolecular chain of a first ceramic having free carbon, and a second precursor macromolecular chain of a second ceramic having free silicon, the first macromolecular chain being bonded to the second macromolecular chain by cross-linking bridges including a bonding structure of formula *1—X—*2; in this formula, X designates boron or aluminium, -*1 designates the bond to the first macromolecular chain and -*2 the bond to the second macromolecular chain.

Abstract: A continuous, solvent-free and non-enzymatic method for synthesizing a compound of formula (I): Ra-POLYPEP-Rc (I) wherein: POLYPEP is a poly-amino acid compound, Ra and Rc are as specified, the method including the steps of: a) feeding an extrusion reactor with (1) a compound of formula (II) Ra-PEPNt-Rg (II) wherein; PEPNt is a mono- or a poly-amino acid compound, Ra and Rg are as specified, and (2) a compound of formula (III) H-PEPCt-Rc (III) wherein: PEPCt is a mono- or a poly-amino acid compound, and Rc is as defined in the absence of any solvent, so that the compound of formula (II) and the compound of formula (III) react together for generating a compound of formula (I), and b) collecting the compound of formula (I) from the extrusion reactor.

Abstract: The invention relates to a process for the recovery of CO2 by biological reduction comprising a step of bringing a liquid phase containing the bacterium Stenotrophomonas maltophilia into contact with a CO2-containing gas phase under conditions allowing the production of formate and/or methane from said CO2. The process according to the invention can be implemented in particular in a closed reactor or a semi-closed reactor or a continuous reactor, electrochemically assisted or not.

Abstract: The invention relates to compounds exhibiting kallikrein inhibitory activity, and to compositions comprising at least one of these compounds for use in the treatment of diseases or disorders in which kallikrein activity is dysregulated, particularly neurodegenerative and inflammatory diseases.

Abstract: The present invention relates to a microfluidic chip for attracting and destroying a specific biological element, said chip comprising: a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element at least one network of microchannels (2) arranged between the reservoir (1) and the external environment (3) of the chip and allowing the chemoattractant compound to pass to said environment and the biological element present in said environment to pass to the reservoir (1) at least one electrode (4) arranged between the reservoir (1) and the network of microchannels (2) or at the same location as the network of microchannels (2), said electrode (4) being capable of generating an electric field so as to destroy the biological element during its passage to the reservoir (1).

Abstract: Chemical compounds are provided belonging to the group of nucleotide analogues. More specifically, acylnucleoside phosphonate compounds are disclosed and also their method of preparation and their use as medicaments, in particular for the prevention and/or the treatment of diseases caused by infection by an organism that is auxotrophic for purines, such as Plasmodium falciparum. Also disclosed are pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

Abstract: The present invention relates to the use of a fluorinated copolymer in the manufacture of a solid polymer film, to give said film properties of adhesion to a metal surface or to glass. It also relates to a process for improving the adhesion of a fluoropolymer to a metal, polymer or glassy substrate, and also to a composite part comprising a solid polymer film in direct contact with at least one metal or glassy element.

Abstract: The present description relates to a method for extracting at least one substance of interest, the method comprising the following steps: —providing an admixture comprising water, a source comprising the at least one substance of interest or at least one precursor thereof, at least one surfactant and at least one lipophilic compound; —the emulsification of the admixture, leading to the formation of an emulsion; wherein the emulsion comprises: —a continuous aqueous phase; and a discontinuous lipidic phase comprising the at least one lipophilic compound, the at least one surfactant and at least one substance of interest extracted from the source during the emulsification; wherein the method further comprises the addition of at least one cryoprotectant to the admixture and the lyophilisation of the emulsion.

Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

Abstract: The present description relates to an emulsion comprising an amphiphilic compound, a first phase comprising droplets including at least one perfluorocarbon compound and a second phase, which is aqueous. The droplets have a diameter d4,3 of between 0.5 pm and 5.5 pm, and the at least one perfluorocarbon compound has a boiling point above 100° C. The present description also relates to such an emulsion for use as an improving agent in ultrasound ablation surgery (FIG. 3).

Abstract: A filter for the filtration of a fluid, such as a liquid, includes or composed of a support element made of a porous ceramic material, the element having a tubular or parallelepipedal shape delimited by an external surface and including, in its internal portion, a set of adjacent channels with axes parallel to one another and separated from one another by walls of the porous inorganic material, wherein at least a portion of the channels and/or at least a portion of the external surface are covered with a porous separating membrane layer, wherein the layer is made of a material essentially composed of sintered grains of silicon carbide (SiC), and the weight content of elemental oxygen of the layer is less than 0.5%.

Abstract: The present invention relates to peptidomimetic macrocycles comprising at least one macrocycle-forming linker and an amino acid sequence chosen from the group consisting of: i) an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, or 95% sequence identity to a human sequence IRAK2 54-71 (SEQ ID No 1) and 100% identity with the amino acids in the positions 5-6, 9-11, 14-15 or ii) an amino acid sequence with at least about 50%, 60%, 70, 80%, 90%, or 95% sequence identity to a human sequence IRAKM 66-83 (SEQ ID No2) and 100% identity with the amino acids in the positions 5-6, 9-11, 13-14, wherein the peptidomimetic macrocycle comprises an ?-helix and at least two natural or two non-natural amino acids crosslinked by a macrocycle-forming linker. It also concerns method of preparation of said peptidomimetic macrocycles and uses thereof, pharmaceutical composition and uses thereof, in particular as inhibitors of inflammatory pathways.

Abstract: A continuous, solvent-free and non-enzymatic method for synthesizing a compound of formula (I): Ra-POLYPEP-Rc (I) wherein: POLYPEP is a poly-amino acid compound, Ra and Rc are as specified, the method including the steps of: a) feeding an extrusion reactor with (1) a compound of formula (II) Ra-PEPNt-Rg (II) wherein; PEPNt is a mono- or a poly-amino acid compound, Ra and Rg are as specified, and (2) a compound of formula (III) H-PEPCt-Rc (III) wherein: PEPCt is a mono- or a poly-amino acid compound, and Rc is as defined in the absence of any solvent, so that the compound of formula (II) and the compound of formula (III) react together for generating a compound of formula (I), and b) collecting the compound of formula (I) from the extrusion reactor.

Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R? is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.

Abstract: A method for extracting the tantalum from an acid aqueous phase A1 comprising at least one step comprising the bringing of the aqueous phase A1 into contact with a phase A2 not miscible with water, and then the separation of the aqueous phase A1 from the phase A2, the phase A2 consisting of one ionic liquid or a mixture of ionic liquids as an extractant. A method for recovering the tantalum that implements this extraction method and to a use of an ionic liquid or of a mixture of ionic liquids as an extractant, in order to extract the tantalum from such an aqueous phase A1.

Abstract: A process for preparing a crosslinked fluoropolymer film, including the successive steps of: (1) formulating an ink containing: (a) the product of the reaction of triethylamine with at least one fluorinated copolymer obtained by radical copolymerization of monomers including: (i) vinylidene fluoride (VDF), (ii) trifluoroethylene (TrFE), (iii) at least one chlorinated monomer of formula —CXCl?CX1X2 where X, X1 and X2 independently denote H, F or CF3, wherein at most one of X, X1 and X2 denotes CF3; (b) at least one crosslinking agent; (c) at least one photoinitiator; and (d) at least one organic solvent; (2) applying said ink in film form to a substrate; and (3) UV-irradiating said film. Also, the film capable of being obtained according to this process, and also to the uses thereof, in particular in the manufacture of (opto)electronic devices and more particularly in the manufacture of a gate dielectric layer in a field-effect transistor.

Abstract: Disclosed is a composition based on copolymers including at least one A-B block copolymer, wherein block A is a polyester and block B is a polyoxyethylene (PEG), and wherein the total molecular mass in weight of the PEG is higher than or equal to 50 kDa, and the ethylene oxide motif/ester motif molar ratio is between 0.5 and 5. The invention also relates to an anti-adhesive material including such a composition, used for the prevention of tissue adhesions and especially for the prevention of intrauterine synechiae.